Lexaria Bioscience Corp — Balance Sheet (NASDAQ:LEXX) | MetaTrader

Open full chart

Financials

Overview Отчетность Statistics Dividends

Quarterly Annual

Total assets 2.83 M13.27 M7.83 M3.08 M8.87 M4.18 M Total liabilities 345.98 K203.26 K201.44 K403.91 K1.21 M1.57 M Total equity 2.48 M12.86 M7.63 M2.68 M7.66 M2.6 M Total liabilities & shareholders' equities 2.83 M13.27 M7.83 M3.08 M8.87 M4.18 M Total debt —————— Net debt ——————

Новости

Акционеры Lexaria Bioscience одобрили выборы совета директоров

Lexaria Bioscience shareholders approve board elections and auditor at annual meeting

DehydraTECH от Lexaria снижает побочные эффекты препаратов GLP-1

Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs

Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Abivax (NASDAQ:ABVX), Rich Sparkle Holdings (NASDAQ:ANPA)

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Agios Pharmaceuticals (NASDAQ:AGIO), Capital One Finl (NYSE:COF)

H.C. Wainwright снизил целевую цену акций Lexaria Bioscience до $1,50

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright

DehydraTECH-семаглутид показывает на 48% меньше побочных эффектов

DehydraTECH-semaglutide shows 48% fewer side effects than Rybelsus

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Lexaria Bioscience (NASDAQ:LEXX)

Lexaria Bioscience закрывает прямое размещение на $3,5 млн